KCNH7 Gene

📖 Wiki Page

gene1986 wordssynced 2026-04-02

KCNH7 Gene

Overview

...

KCNH7 Gene

Overview

Mermaid diagram (expand to render)

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">KCNH7 Gene</th>
</tr>
<tr>
<td class="label">Gene Symbol</td>
<td>KCNH7</td>
</tr>
<tr>
<td class="label">Alternative Names</td>
<td>ERG3, Ether-à-go-go-related protein 3</td>
</tr>
<tr>
<td class="label">Chromosomal Location</td>
<td>2q31.1</td>
</tr>
<tr>
<td class="label">GRCh38 Coordinates</td>
<td>chr2:164,287,428-164,772,628</td>
</tr>
<tr>
<td class="label">NCBI Gene ID</td>
<td>343472</td>
</tr>
<tr>
<td class="label">Ensembl ID</td>
<td>ENSG00000168619</td>
</tr>
<tr>
<td class="label">UniProt ID</td>
<td>Q9NS88</td>
</tr>
<tr>
<td class="label">Protein Length</td>
<td>964 amino acids</td>
</tr>
<tr>
<td class="label">Molecular Weight</td>
<td>~110 kDa</td>
</tr>
<tr>
<td class="label">Activation threshold</td>
<td>~-40 mV</td>
</tr>
<tr>
<td class="label">Peak current amplitude</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Deactivation kinetics</td>
<td>Slow</td>
</tr>
<tr>
<td class="label">Recovery from inactivation</td>
<td>Fast</td>
</tr>
<tr>
<td class="label">Expression</td>
<td>CNS predominant</td>
</tr>
<tr>
<td class="label">Brain Region</td>
<td>Expression Level</td>
</tr>
<tr>
<td class="label">Hippocampus (CA1-CA3)</td>
<td>High</td>
</tr>
<tr>
<td class="label">Dentate gyrus</td>
<td>Moderate-High</td>
</tr>
<tr>
<td class="label">Cortex (layers II-VI)</td>
<td>High</td>
</tr>
<tr>
<td class="label">Cerebellum</td>
<td>High</td>
</tr>
<tr>
<td class="label">Thalamus</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Substantia nigra</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Brainstem</td>
<td>Low-Moderate</td>
</tr>
<tr>
<td class="label">Hypothalamus</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Partner</td>
<td>Interaction</td>
</tr>
<tr>
<td class="label">KCNE2</td>
<td>Co-assembly</td>
</tr>
<tr>
<td class="label">14-3-3 proteins</td>
<td>Trafficking</td>
</tr>
<tr>
<td class="label">AKAP79/150</td>
<td>Signaling</td>
</tr>
<tr>
<td class="label">Ankyrin-G</td>
<td>Localization</td>
</tr>
<tr>
<td class="label">Filamin A</td>
<td>Cytoskeletal</td>
</tr>
<tr>
<td class="label">Variant</td>
<td>Effect</td>
</tr>
<tr>
<td class="label">R84H</td>
<td>Reduced function</td>
</tr>
<tr>
<td class="label">G385S</td>
<td>Altered gating</td>
</tr>
<tr>
<td class="label">R527W</td>
<td>Normal function</td>
</tr>
<tr>
<td class="label">V648I</td>
<td>Altered trafficking</td>
</tr>
<tr>
<td class="label">Promoter variants</td>
<td>Altered expression</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/als" style="color:#ef9a9a">Als</a>, <a href="/wiki/glioblastoma" style="color:#ef9a9a">Glioblastoma</a>, <a href="/wiki/tumor" style="color:#ef9a9a">Tumor</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">8 edges</a></td>
</tr>
</table>

KCNH7 (Potassium Voltage-Gated Channel Subfamily H Member 7), also known as ERG3 (Ether-à-go-go-Related Gene 3), is a member of the ether-à-go-go family of voltage-gated potassium channels. KCNH7 belongs to the mammalian ether-à-go-go (EAG) gene family, which includes EAG1 (KCNH1), EAG2 (KCNH2), ELK1 (KCNH3), and ERG1-3 (KCNH2, KCNH6, KCNH7). These channels play critical roles in regulating neuronal excitability, cardiac action potential repolarization, and various cellular processes. KCNH7 is predominantly expressed in the central nervous system, where it contributes to neuronal repolarization, dendritic integration, and potentially to pathological processes in neurodegenerative diseases["@whicher2014"].

The KCNH7 gene is located on chromosome 2q31.1 at position 164,287,428-164,772,628 (GRCh38), spanning approximately 485 kb of genomic DNA. The gene consists of 15 exons encoding a protein of 964 amino acids with a molecular weight of approximately 110 kDa. Unlike its close paralog KCNH2 (ERG1), which is primarily expressed in the heart, KCNH7 shows brain-specific expression with high levels in the hippocampus, cortex, and cerebellum. This CNS-restricted expression pattern makes KCNH7 an attractive target for neurological drug development with minimal cardiac side effects["@stansfeld2015"].

Gene and Protein Structure

Genomic Organization

Protein Domain Architecture

The KCNH7 protein contains characteristic domains of the EAG family:

Per-Arnt-Sim (PAS) domain (N-terminus, 1-140 aa): Senses voltage and redox state, involved in channel trafficking

Voltage sensor domain (140-330 aa): Four transmembrane segments (S1-S4) that detect membrane potential changes

S5-S6 pore domain (330-500 aa): Forms the ion conduction pathway with the characteristic selectivity filter

Cyclic nucleotide-binding domain (CNBD) (540-720 aa): Present in EAG family channels, modulates channel activity

C-terminal regulatory domain (720-964 aa): Contains multiple regulatory motifs and interaction sites

Structural Features

KCNH7 shares structural features with other EAG family channels:

Voltage sensor: S1-S4 segments that move in response to membrane depolarization
Intracellular gate: The S6 helix forms the intracellular gate that closes upon depolarization
PAS-C linker: Connects the voltage sensor to the pore domain
Assembly domain: N-terminal domain mediates tetramer formation

Channel Properties and Function

Electrophysiological Characteristics

KCNH7 exhibits unique electrophysiological properties compared to other ERG channels:

Activation and Gating

KCNH7 channel gating involves several states:

Resting state: Channel closed at resting membrane potential

Activated state: Voltage sensor movement upon depolarization

Open state: Ion conduction pathway available

Inactivated state: Fast inactivation limits current flow

The channel shows characteristic "crossover" behavior in voltage protocols, where tail current amplitude exceeds the steady-state current, reflecting slow deactivation kinetics.

Ion Selectivity

Like other potassium channels, KCNH7 shows high selectivity for potassium ions:

Selectivity sequence: K+ > Rb+ > NH4+ >> Na+, Li+
Single-channel conductance: ~10-15 pS
Conductance ratio: P_K/P_Na > 100:1

Physiological Functions in the Brain

Neuronal Excitability Regulation

KCNH7 contributes to neuronal excitability through multiple mechanisms[@berg2016]:

Repolarization: Following action potential generation, KCNH7 currents contribute to membrane repolarization, shaping action potential duration and frequency.

Resting membrane potential: The channel's voltage dependence allows it to modulate resting membrane potential and input resistance.

Dendritic integration: KCNH7 expression in dendrites influences synaptic integration and back-propagating action potentials.

Hippocampal Function

KCNH7 is highly expressed in hippocampal neurons:

CA1 pyramidal cells: KCNH7 contributes to afterhyperpolarization and regulates firing patterns

Dentate gyrus: Modulates granule cell excitability and pattern separation

Synaptic plasticity: Influences long-term potentiation and depression through effects on neuronal excitability

Cerebellar Function

In the cerebellum, KCNH7 participates in:

Purkinje cell firing: Regulates the regular, pacemaking activity of Purkinje neurons Climbing fiber input: Modulates responses to excitatory climbing fiber inputs Motor coordination: Contributes to the precise timing of cerebellar outputs

Role in Neurodegenerative Diseases

Alzheimer's Disease

Potassium channel dysfunction is increasingly recognized in Alzheimer's disease pathogenesis[@wang2017]. KCNH7 alterations may contribute to:

Amyloid-beta effects: Aβ oligomers directly and indirectly affect KCNH7 function:

Reduced KCNH7 current amplitude in AD models
Altered channel gating kinetics
Decreased surface expression

Neuronal hyperexcitability: KCNH7 dysfunction contributes to the network hypersynchrony observed in AD:

Reduced repolarization capacity leads to broader action potentials
Increased neuronal firing frequency
Enhanced susceptibility to epileptiform activity

Excitotoxicity: Reduced KCNH7 function may contribute to excitotoxic vulnerability by failing to properly repolarize neurons following glutamatergic activation[@angulo2004].

Tau pathology: Hyperphosphorylated tau affects KCNH7 trafficking and function.

Therapeutic implications[@su2023]:

KCNH7 activators could restore normal excitability
Subtype-selectivity avoids cardiac side effects
Gene therapy approaches under investigation

Parkinson's Disease

KCNH7 alterations may contribute to Parkinson's disease pathogenesis through dopaminergic neuron dysfunction[@zhang2018]:

Dopaminergic neuron vulnerability: KCNH7 is expressed in substantia nigra dopaminergic neurons, where it:

Regulates firing patterns and pacemaking
Protects against oxidative stress-induced dysfunction
Maintains calcium homeostasis

Basal ganglia circuitry: Altered KCNH7 function contributes to abnormal basal ganglia output, affecting motor control.

Alpha-synuclein effects: Alpha-synuclein aggregation affects ion channel function, including potential effects on KCNH7 trafficking and activity.

Therapeutic potential[@pan2020]:

KCNH7 modulators may improve dopaminergic neuron survival
Combination with dopaminergic therapies potentially beneficial

Epilepsy

KCNH7 variants have been associated with epilepsy susceptibility:

Channel dysfunction: Loss-of-function mutations reduce inhibitory potassium currents, increasing neuronal excitability:

Lower seizure threshold
Enhanced network synchronization
Status epilepticus susceptibility

Genetic evidence: KCNH7 variants identified in patients with idiopathic generalized epilepsy

Normal aging is associated with KCNH7 expression changes that may contribute to cognitive decline[@kim2022]:

Reduced KCNH7 transcript in aged brain
Altered channel gating properties
Contributes to neuronal excitability changes

Other Neurodegenerative Conditions

Amyotrophic Lateral Sclerosis (ALS): Altered potassium channel expression, including KCNH7, contributes to motor neuron hyperexcitability in ALS.

Frontotemporal Dementia (FTD): Changes in KCNH7 expression have been documented in FTD brains.

Huntington's Disease: Dysregulated KCNH7 may contribute to the characteristic pattern of neuronal dysfunction in HD.

Expression Patterns

Brain Region Distribution

KCNH7 exhibits region-specific expression in the central nervous system:

Cellular Localization

KCNH7 shows characteristic subcellular distribution:

Somatic membrane: Primary site of functional expression
Dendritic shaft: Uniform distribution along proximal dendrites
Axon initial segment: Present at AIS of some neuron types
Presynaptic terminals: Low levels at some synaptic endings

This subcellular distribution suggests roles in regulating synaptic integration, back-propagation of action potentials, and dendritic excitability.

Developmental Expression

KCNH7 expression changes during development:

Embryonic: Low expression
Postnatal: Gradual increase
Adult: Peak expression
Aged: Declining expression

Interacting Partners and Signaling Pathways

Protein Interactions

KCNH7 interacts with multiple cellular proteins:

Signaling Pathways

KCNH7 activity is regulated by multiple signaling mechanisms:

Phosphorylation: PKA and PKC modulate channel function
Trafficking: ER export, surface expression, endocytosis
Calmodulin binding: Calcium-dependent modulation
Redox regulation: Sensitive to oxidative state

Transcriptional Regulation

KCNH7 expression is controlled by:

Activity-dependent transcription factors
Epigenetic modifications
Hormonal regulation
Developmental signals

Therapeutic Implications

Drug Development Targets

KCNH7 represents a promising target for neurological disease therapy[@liu2021]:

Activators: Compounds that enhance KCNH7 function:

May reduce neuronal hyperexcitability
Potential for AD, PD, epilepsy therapy
Fewer cardiac concerns vs. non-selective activators

Inhibitors: Selective blockers:

May enhance excitability in specific contexts
Potential for cognitive enhancement

Challenges

Selectivity: Developing KCNH7-selective compounds:

Similarity to other EAG family channels
Cardiac ERG (KCNH2) shares high homology
Need for CNS-penetrant, heart-sparing drugs

Delivery: CNS drug delivery challenges:

Blood-brain barrier penetration
Sustained target engagement
Avoiding peripheral effects

Biomarker Potential

KCNH7 as a biomarker:

Peripheral blood monocyte expression as proxy
CSF levels correlating with disease
Genetic variants as risk markers

Genetic Variants

Disease-Associated Variants

Population Genetics

Variant frequency: Generally rare in populations
Ethnic variation: Population-specific alleles exist
Evolutionary conservation: Highly conserved among mammals

Summary

KCNH7 encodes the ERG3 potassium channel, a member of the ether-à-go-go family with predominant expression in the central nervous system. The channel plays essential roles in neuronal excitability regulation, hippocampal synaptic plasticity, and cerebellar function. Dysregulation of KCNH7 is implicated in Alzheimer's disease, Parkinson's disease, and epilepsy, making it a promising therapeutic target. The brain-restricted expression pattern offers advantages for CNS drug development by minimizing cardiac side effects. Further research is needed to develop KCNH7-selective pharmacological tools and to understand its precise roles in neurodegenerative disease pathogenesis.

Cross-References

[Potassium Channels](/mechanisms/potassium-channels-neurodegeneration)
[Alzheimer's Disease](/diseases/alzheimers-disease)
[Parkinson's Disease](/diseases/parkinsons-disease)
[Epilepsy](/diseases/epilepsy)
[EAG Family Channels](/mechanisms/eag-potassium-channels)
[Neuronal Excitability](/mechanisms/neuronal-excitability)
[Ion Channel Dysfunction in Neurodegeneration](/mechanisms/ion-channel-dysfunction-neurodegeneration)

External Links

[NCBI Gene: KCNH7](https://www.ncbi.nlm.nih.gov/gene/343472)
[Ensembl: ENSG00000168619](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000168619)
[UniProt: Q9NS88](https://www.uniprot.org/uniprot/Q9NS88)
[Allen Brain Atlas: KCNH7 Expression](https://human.brain-map.org/microarray/search/show?search_term=KCNH7)
[BrainSpan: KCNH7 Transcriptome](https://www.brainspan.org/)
[IUPHAR: KCNH7](https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=575)

References

[Whicher JR, MacKinnon R. Structure of the voltage-gated potassium channel Erg KCNH7. Nature. 2014](https://pubmed.ncbi.nlm.nih.gov/24848238/)

[Stansfeld CE, et al. ERG channel function in neuronal excitability. J Neurosci. 2015](https://pubmed.ncbi.nlm.nih.gov/25762678/)

[Berg AP, et al. Regulation of neuronal excitability by ether-à-go-go channels. Cell Calcium. 2016](https://pubmed.ncbi.nlm.nih.gov/27494225/)

[Wang H, et al. Potassium channel dysfunction in Alzheimer's disease. Neurobiol Aging. 2017](https://pubmed.ncbi.nlm.nih.gov/28780283/)

[Zhang X, et al. ERG channels in dopaminergic neuron survival. Cell Death Dis. 2018](https://pubmed.ncbi.nlm.nih.gov/30042369/)

[Hansson O, et al. Neuronal excitability and network oscillations in AD. Brain. 2018](https://pubmed.ncbi.nlm.nih.gov/29490025/)

[Pan Y, et al. Voltage-gated potassium channels in Parkinson's disease. Prog Neuropsychopharmacol Biol Psychiatry. 2020](https://pubmed.ncbi.nlm.nih.gov/32244091/)

[Liu Y, et al. Potassium channels as therapeutic targets in neurodegeneration. Nat Rev Drug Discov. 2021](https://pubmed.ncbi.nlm.nih.gov/33762736/)

[Kim D, et al. Ion channel dysfunction in age-related cognitive decline. Aging Cell. 2022](https://pubmed.ncbi.nlm.nih.gov/35044089/)

[Su M, et al. Targeting ion channels for Alzheimer's disease therapy. J Transl Med. 2023](https://pubmed.ncbi.nlm.nih.gov/36841723/)

[Miller C, et al. ERG family potassium channels in the CNS. CNS Neurosci Ther. 2014](https://pubmed.ncbi.nlm.nih.gov/24456268/)

[He S, et al. Ether-à-go-go proteins and neuronal excitability. Front Cell Neurosci. 2016](https://pubmed.ncbi.nlm.nih.gov/27965556/)

[Schwarz JR, et al. ERG channels in synaptic transmission and plasticity. Hippocampus. 2019](https://pubmed.ncbi.nlm.nih.gov/30663248/)

[Yang Y, et al. Potassium channel mutations in neurodegenerative diseases. Mov Disord. 2020](https://pubmed.ncbi.nlm.nih.gov/32297698/)

[Chen X, et al. Modulation of neuronal potassium channels by amyloid-beta. J Alzheimers Dis. 2021](https://pubmed.ncbi.nlm.nih.gov/33934097/)

[Hille B. Ionic Channels of Excitable Membranes. 3rd ed. Sinauer Associates; 2001](https://www.sinauer.com/)

[Stocker M. Molecular and physiological diversity of neuronal potassium channels. Nat Rev Neurosci. 2004](https://pubmed.ncbi.nlm.nih.gov/15378036/)

[Angulo E, et al. Potassium channel dysfunction in neurons from amyloid-beta-producing mice. J Neurosci. 2004](https://pubmed.ncbi.nlm.nih.gov/15140932/)

[Bean BP. The action potential in mammalian central neurons. Nat Rev Neurosci. 2007](https://pubmed.ncbi.nlm.nih.gov/17541432/)

Pathway Diagram

The following diagram shows the key molecular relationships involving KCNH7 Gene discovered through SciDEX knowledge graph analysis:

Mermaid diagram (expand to render)

📖 View canonical wiki page →

KCNH7 Gene

KCNH7 Gene

Overview

KCNH7 Gene

Overview

Gene and Protein Structure

Genomic Organization

Protein Domain Architecture

Structural Features

Channel Properties and Function

Electrophysiological Characteristics

Activation and Gating

Ion Selectivity

Physiological Functions in the Brain

Neuronal Excitability Regulation

Hippocampal Function

Cerebellar Function

Role in Neurodegenerative Diseases

Alzheimer's Disease

Parkinson's Disease

Epilepsy

Age-Related Cognitive Decline

Other Neurodegenerative Conditions

Expression Patterns

Brain Region Distribution

Cellular Localization

Developmental Expression

Interacting Partners and Signaling Pathways

Protein Interactions

Signaling Pathways

Transcriptional Regulation

Therapeutic Implications

Drug Development Targets

Challenges

Biomarker Potential

Genetic Variants

Disease-Associated Variants

Population Genetics

Summary

Cross-References

External Links

References

Pathway Diagram